The Globe and Mail reports in its Wednesday, Sept. 25, edition that Stifel analyst Justin Keywood has given his ATS share target a $2 trim to $58 ahead of an investor tour in Europe next week. The Globe's David Leeder writes that Mr. Keywood continues to rate ATS "buy." Analysts on average target ATS shares at $57.50. Mr. Keywood says in a note: "We anticipate deep insight into auto-injector assembly lines for GLP-1 as the highest growth area, along with nuclear medicine and radio pharmaceutical technologies and processing/packaging for food products. We also roll out new F2026 forecasts and adjust F2025 estimates as a transition year, from material EV headwinds, anticipated to comprise 22 per cent of sales vs. 31 per cent year-over-year. Our F2026 estimates assumes EV declines moderate, as OEM ordering inertia, heading into the U.S. election, could subside. We expect continued strength in life sciences, including from record FQ1 backlog. M&A continues to be part of our thesis and could materially change forecasts." The Globe reported on April 17 that Mr. Keywood had reaffirmed his "buy" recommendation for ATS. In the item, Mr. Keywood called ATS one of his "top picks." The shares could then be had for $41.40.